Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th.

CytomX Therapeutics Trading Down 1.3 %

CTMX opened at $0.85 on Tuesday. The firm has a 50 day moving average of $1.04 and a two-hundred day moving average of $1.16. The firm has a market capitalization of $66.29 million, a PE ratio of 4.98 and a beta of 1.03. CytomX Therapeutics has a 12-month low of $0.79 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. During the same quarter last year, the company posted $0.04 earnings per share. As a group, analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of CytomX Therapeutics in the 3rd quarter valued at about $104,000. Geode Capital Management LLC raised its stake in shares of CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 16,359 shares during the period. FMR LLC lifted its position in shares of CytomX Therapeutics by 17.3% during the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 41,949 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares during the period. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.